SCHEDULE: Frazier Life Sciences Amends Jade Biosciences Stake
Beneficial Ownership Disclosure
Frazier Life Sciences and its affiliates filed an amended Schedule 13G, clarifying their beneficial ownership in Jade Biosciences, Inc. common stock.
Summary
- Frazier Life Sciences Public Fund, L.P. and its related entities beneficially own 1,340,703 shares, representing 4.2% of Jade Biosciences' common stock.
- Frazier Life Sciences Public Overage Fund, L.P. and its related entities beneficially own 395,508 shares, representing 1.2% of the common stock.
- Frazier Life Sciences X, L.P. and its related entities beneficially own 11,897 shares, representing 0.0% of the common stock.
- Frazier Life Sciences XI, L.P. and its related entities beneficially own 24,008 shares, representing 0.1% of the common stock.
- The total outstanding shares of Jade Biosciences, Inc. common stock used for calculation is 32,235,927 as of April 28, 2025.
- The filing corrects and clarifies that certain individual members of investment committees (Albert Cha, James Brush, Daniel Estes) are not attributed beneficial ownership of shares held by the funds, rectifying previous overstatements.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine amendment to a passive beneficial ownership disclosure, clarifying ownership attribution without indicating any change in investment strategy or company performance.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership by an investment fund in a biotechnology company. It does not provide operational or strategic updates for Jade Biosciences, Inc., but rather details the passive investment stake held by Frazier Life Sciences and its affiliated entities.
Stakeholder Impact
- Minimal direct impact on shareholders as this is a clarification of existing passive ownership rather than a new investment or divestment.
- No direct impact on employees, customers, suppliers, or creditors of Jade Biosciences, Inc. as the filing pertains solely to beneficial ownership disclosure.
Key Dates
| Date | Description |
|---|---|
| 2025-04-28 | Date of total shares outstanding calculation for Jade Biosciences, Inc. |
| 2025-06-30 | Date of event requiring the filing of this statement. |
| 2025-08-14 | Date of signing of the Schedule 13G amendment. |
Keywords
Jade Biosciences, SEC Filing, Schedule 13G, Beneficial Ownership, Frazier Life Sciences, Common Stock, Investment Fund, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.